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Strategies to improve medication adherence 
in patients with schizophrenia: the role 
of support services
Peggy el-Mallakh
Jan Findlay
College of Nursing, University 
of Kentucky, Lexington, KY, USA
Abstract: The purpose of this review is to describe research over the past 10 years on the role 
of support services in promoting medication adherence in mental health consumers diagnosed 
with schizophrenia. A literature search was conducted using the terms “medication adherence,” 
“schizophrenia,” and “support services,” using Medline, PubMed, and CINAHL. Reference lists 
from published studies were also reviewed to identify additional research studies. Twenty-two 
articles focused on support-service intervention studies, and these were selected for review. 
Available support-service interventions include adherence therapy, electronic reminders via 
text messages and telephones, cognitive–behavioral and motivational strategies, and financial 
incentives. Support-service intervention strategies need to be tailored to the specific needs of 
mental health consumers with schizophrenia. More research is needed to investigate effective 
support services to enhance long-term adherence and adherence to medications for medical 
illnesses in this population.
Keywords: schizophrenia, medication adherence, support services, therapy, interventions
Introduction
Adherence to pharmacological treatment is essential for alleviation of psychotic 
symptoms in schizophrenia. First-line antipsychotic medications are effective in 
approximately 70%–80% of persons diagnosed with schizophrenia (PWS); however, 
an estimated 50% of those who respond well to medications are nonadherent to their 
treatment regimen.1 Wide variations have been observed in patterns of medication 
adherence among PWS. Nonadherence can range from patients who refuse to take 
medications due to lack of acceptance of the need for medication, to patients who 
recognize the need for medication and are committed to treatment but are nonadher-
ent due to forgetfulness or financial constraints.2 The consensus definition for adher-
ence maintains that PWS can be considered adherent if they take more than 80% of 
prescribed medications; partial adherence is defined as taking 50% of prescribed 
medications.3 Velligan and colleagues also report a consensus among experts that 
nonadherence can be defined as being off of medications for 1 week.3
Factors associated with medication nonadherence
As the definitions of adherence suggest, the decision to take medications in PWS is 
a complex phenomenon that involves multiple patient, environmental, provider, and 
medication-related factors. Patient-related factors include some demographic char-
acteristics, such as newly starting treatment, younger age at onset of illness, alcohol 
dependence and other illicit substance use, homelessness, low levels of involvement 
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in social activities, independent housing, and financial con-
straints with consequent inability to afford copayments for 
prescriptions.4–9 Membership in a minority ethnic group also 
contributes to poor medication adherence; in a large study 
of 34,128 US veterans with schizophrenia, Valenstein et al10 
reported that the relative risk ratio for consistently poor 
adherence was 3.81 for African Americans compared to 
whites and 3.54 for Hispanics compared to whites. Lack of 
family support for adherence, or having no family, further 
contributes to nonadherence. Glick et al11 and Moritz et al12 
observed that a positive attitude toward positive symptoms, 
particularly the perception of importance and power resulting 
from psychotic symptoms, also contributes to nonadherence. 
In addition, a study by Jόnsdόttir et al6 found that nonadher-
ent PWS had significantly higher IQs, executive function-
ing, memory, and verbal learning/fluency compared to fully 
adherent PWS.
Perceptions about illness and medications are very impor-
tant factors that influence adherence. For example, adherence 
is higher among PWS who have insight and an awareness 
of the need to take medications to alleviate symptoms and 
avoid hospitalization.7,13–15 In addition, favorable attitudes 
toward mediations and the expectation that medications are 
effective in reducing symptoms contribute to adherence.15,16 
Intolerable side effects are a major reason for discontinuing 
medications.12,15 For example, side effects associated with 
typical antipsychotics, such as extrapyramidal symptoms, 
sedation, and elevated prolactin levels, are particularly 
problematic. Metabolic side effects of atypical antipsychot-
ics, including weight gain, further contribute to lack of 
adherence.17 However, some research suggests that recogni-
tion of the benefits of medications in alleviating troublesome 
psychotic symptoms improves willingness to tolerate the 
side-effect burden for the sake of mental wellness.18 Simi-
larly, Liu-Seifert et al19 compared adherence among 1,103 
people treated with olanzapine and 1,090 people treated with 
other atypical antipsychotic medications (risperidone, quetia-
pine, ziprasidone, or aripiprazole). Findings suggested that 
an improvement in the positive symptom rating subscale of 
the Positive and Negative Syndrome Scale was the strongest 
predictor of treatment adherence, regardless of the medica-
tion that was prescribed.
Much research supports the critical need for a strong 
and positive therapeutic relationship in the promotion of 
medication adherence.20,21 Misdrahi et al7 found that thera-
peutic alliance was significantly associated with medication 
adherence (r=0.663) among 38 PWS. Similarly, Dassa et al16 
found that nonadherence to medications increased with 
a low level of therapeutic alliance (odds ratio =0.45, 95% 
confidence interval =0.32–0.64) among 291 PWS. Research 
also suggests that patients value support from prescribers 
regarding medication, particularly when prescribers provided 
accurate information about potential side effects of medica-
tion, expressed understanding of the patient perspective, 
and listened to patients’ concerns about the medications. In 
addition, Day et al20 reported that the experience of admis-
sion to the hospital is an important factor that influences 
willingness to take medications; the perception of coercion, 
lack of a voice in treatment decisions, and negative pressure 
to enter the hospital are all associated with nonadherence to 
psychiatric medications.
Adherence to medications for medical 
illnesses
High rates of cardiometabolic problems among PWS have 
prompted clinicians to focus on adherence to treatment for med-
ical illnesses in this population. Research investigating adher-
ence to medical care has yielded varying results. Pratt et al22 
in a study of 72 participants with serious mental illnesses, 
reported adherence rates of 57% for psychiatric medications 
and 64% for medications for medical illnesses. Hansen et al 23 
in a study of 87,015 PWS with comorbid medical illnesses, 
found that adherence to medications for hypertension, hyper-
lipidemia, and diabetes was significantly greater among those 
who were adherent to antipsychotic medications, with an 
adjusted odds ratio of 6.9. In a study of 11,454 US veterans, 
Kreyenbuhl et al24 found poor adherence to medications for 
Type 2 diabetes mellitus (T2DM) in 43% of veterans with 
schizophrenia and T2DM, compared to poor adherence rates 
among 52% of veterans with T2DM and no mental illness. 
Similarly, Nelson et al25 found that gaps in filled prescriptions 
for antihyperlipidemic medications were 44 days for veter-
ans diagnosed with schizophrenia and T2DM, compared to 
62 days for veterans with T2DM and no mental illness.
Piette et al26 noted that in a study of 1,686 veterans diag-
nosed with schizophrenia and comorbid diabetes and hyper-
tension, differential rates of adherence depended on the type 
of medication prescribed to participants; findings suggest 
that treatment with antihypertensive and diabetes medica-
tions was associated with an increased risk for low adher-
ence compared to antipsychotic medications. Dolder et al27 
found that rates of adherence to antihypertensive agents in 
89 veterans with psychotic disorders were similar to rates 
in 89 randomly selected, age-matched veterans without 
psychotic disorders; however, blood pressure control was 
significantly poorer over a 1-year period in the participants 
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with psychotic disorders. In contrast, Dolder et al28 found 
that among 76 middle-aged and older veterans with schizo-
phrenia, 12-month adherence rates ranged from 52%–64% 
for antipsychotic medications and medications to treat 
hypertension, diabetes, and hyperlipidemia. Beebe et al29 in a 
study that compared the effectiveness of a telephone interven-
tion to improve medication adherence (n=15) to usual care 
(n=14), found that average adherence rates to medications 
for medical illnesses was 33% for the intervention group and 
22% for the treatment-as-usual (TAU) group throughout the 
duration of the study.
Consequences of nonadherence
Partial or complete lack of adherence to medications is asso-
ciated with several negative outcomes in PWS.8,30 Medication 
nonadherence is associated with an increased risk for relapse 
of psychosis, persistent symptoms, and suicide attempts.8,31 
Among PWS experiencing a first episode of psychosis, 
symptom recurrence rates are an average of 77% within 
1 year of stopping medications, and over 90% within 2 years 
of stopping medications.30 Bodén et al32 found that nonadher-
ence to medications during the first week after discharge from 
an inpatient hospitalization was associated with a high risk 
for rehospitalization within 1 month of discharge. Length of 
hospital stay is also extended due to nonadherence.30 Finally, 
Gilmer et al5 found that average hospital costs in nonadherent 
inpatients were three times higher than costs for adherent 
inpatients, although pharmacy costs were higher among 
adherent compared to nonadherent inpatients.
Current strategies to improve adherence
Several support services are available to address specific 
problems with adherence.33 For example, therapeutic support 
services provide counseling, with the goal of identifying and 
modifying cognitive and motivational barriers to adherence. 
Cognitive-behavioral therapy (CBT) addresses inaccurate 
beliefs and negative perceptions about medications and the 
need for treatment.3 CBT is often used in conjunction with 
motivational interviewing (MI), which seeks to resolve 
ambivalence about taking medications and addresses per-
ceptions about the importance of taking medications and 
confidence in the ability to adhere to a medication regimen.34 
Cognitive adaption training provides tailored environmental 
cues and supports to compensate for cognitive impairments 
that cause memory problems; these include alarms, pillboxes, 
activity checklists, and organization of personal belongings.33 
Adherence/compliance therapy is a multifaceted approach 
that includes CBT, psychoeducation, and MI.3 Support 
services can also address logistic barriers to adherence, such 
as arranging transportation to pharmacies and obtaining 
insurance benefits.3
This review summarizes research from the past 10 years 
on interventions that examined the role of support services in 
promoting adherence to psychiatric medications and medica-
tions for medical illnesses among PWS. A literature search 
was conducted using the terms “medication adherence,” 
“schizophrenia,” and “support services” and “interventions” 
using Medline, PubMed, and CINAHL. Reference lists from 
published studies were also reviewed to identify additional 
research studies. A total of 22 articles were located using 
these search terms and are included in this review.
Results
Findings from this literature review are displayed in 
Tables 1–4. Of the 22 studies reviewed, eleven significantly 
improved adherence to medications in the study samples, and 
five did not result in significant improvements.
Support service interventions
Family and/or clinician support/education
Seven intervention studies examined the effectiveness of 
family and/or clinician support and education (Table 1).35–41 
Two family studies showed promising findings. Farooq et al37 
implemented an intervention to train family members to be 
key care supervisors of medication adherence (coupled with 
free medications). Findings indicated that medication adher-
ence was significantly increased in the intervention group.37 
Kopelowicz et al39 found that culturally adapted multifamily 
groups tailored to Spanish-speaking Mexican Americans, 
who had three individual and family psychotherapy sessions, 
a 1-day family workshop, and 24 family group sessions that 
focused on attitudes, beliefs, planned behaviors, and subjec-
tive norms, had increased adherence compared to multifamily 
groups only or TAU.
Interventions involving clinician support and education 
yielded varying results. Sajatovic et al41 examined the effec-
tiveness of a psychosocial/psychoeducational customized 
adherence enhancement program for homeless people taking 
long-acting antipsychotic injections (LAIs), which focused 
on medication routines, communicating with clinicians, and 
managing adherence in the presence of substance abuse. The 
customized adherence enhancement program was associated 
with good adherence to LAIs in 76% of participants. Oral 
medication adherence improved to only 10% missed medica-
tion doses postintervention compared to 46% missed doses 
prestudy. However, only four out of 30 continued taking 
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LAI 6 months poststudy. In contrast, Byerly et al36 found 
that adherence did not increase after four to six sessions 
of compliance therapy that focused on illness history, and 
medication beliefs, understanding, ambivalence, and stigma 
of treatment. Anderson et al35 found no significant improve-
ments in medication adherence following eight weekly 
sessions of adherence therapy that included problem solv-
ing, exploration of ambivalence toward medication beliefs, 
concerns, and using medications in the future. Similarly, 
Gray et al38 found that there was no significant difference 
in adherence between adherence therapy that included eight 
weekly sessions about problem solving, medication timeline, 
ambivalence, beliefs, and concerns about using them in the 
future versus eight weekly health education sessions. Mittal 
et al40 found that there was no significant difference between 
antipsychotic adherence therapy versus TAU following nine 
weekly sessions of daily, then weekly, face-to-face and 
telephone education, alliance building, and skills training in 
veterans aged 40 years and older.
Technology-based services
A variety of electronics-based strategies were studied, includ-
ing text messages, phone reminders, pill counters, electronic 
pill dispensers, and a computerized program symptom alert 
system (Table 2).29,42–46 Pijnenborg et al44 used text messages 
in an intervention to examine the effectiveness of six weekly 
group sessions focusing on coping with cognitive impair-
ment associated with schizophrenia. The study also involved 
instructions on how to send/receive text messages, including 
a total of 7 weeks of receiving text messages as a reminder 
to adhere to medications and other self-chosen treatment 
goals. Adherence to medications in the intervention group 
was 57% at baseline and 65% during the intervention, but 
fell to 48% at follow-up when text prompts were no longer 
being received. Granholm et al42 found that sending three 
sets of four text messages about medication adherence, 
socialization, and auditory hallucinations to people with 
schizophrenia significantly improved medication adherence 
for those living independently. Similarly, Montes et al43 found 
that after sending daily short-message-service reminders or 
texts for 3 months as a prompt to take medications, there was 
a significantly reduced score on the Medication Adherence 
Questionnaire (a four-item self-report of reasons for medi-
cation adherence failure, with a low score indicating better 
adherence) in the intervention group at 3 months, and at 
6 months adherence was maintained.
Beebe et al29 found that study participants who received 
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el-Mallakh and Findlay
for psychiatric and medical conditions over 3 months had 
significantly higher adherence compared to TAU controls. 
Those in the intervention group were 80% adherent to psy-
chiatric medications and 33% adherent to medications for 
medical conditions.
Stip et al46 found that after 8 weeks of using an electronic 
pill counter to assess medication adherence, 46% were non-
adherent. The mean antipsychotic adherence ratio was 67% 
after 6 weeks. Participants who were adherent at baseline 
had significantly greater adherence versus those who were 
nonadherent at baseline. Španiel et al45 found that after 1 year 
of computer prompts to clinicians to increase antipsychotic 
medication doses when participants reported psychotic symp-
toms (via an electronic message), there was no significant 
difference in medication adherence in the intervention group 
compared to controls.
Motivational interviewing interventions
MI was used in conjunction treatment adherence therapy 
(TAT) and problem solving approaches (Table 3).47–50 
Barkhof et al47 found that there were no significant differ-
ences in medication adherence after 26-week and 6-month 
interventions of MI versus health education. Staring et al50 
examined the effectiveness of 6 months of TAT, which 
includes MI, medication optimization, and behavioral train-
ing, and found that TAT significantly improved medication 
adherence. Findings also indicated that, despite a decrease 
in effectiveness at the 6-month follow-up, adherence in the 
intervention group remained significantly higher than in the 
TAU group.
Hudson et al48 found that clinical interviews with a 
registered nurse who asked people to identify barriers to 
adherence and tailored strategies to overcome them via 
problem solving at each clinic visit (minimum of every 6 
weeks) for 6 months significantly increased adherence at 
the 6-month follow-up. Adherence at 6 months was signifi-
cantly associated with baseline adherence, female sex, and 
no akathisia at baseline. Maneesakorn et al49 examined the 
effectiveness of eight weekly sessions of adherence therapy 
which focused on medication problem-solving, beliefs/
attitudes/ambivalence toward taking medications, and tak-
ing medications in the future. Findings indicated that the 
participants in the adherence-therapy group showed signifi-
cant improvements in positive symptoms, attitudes toward 
medications, and satisfaction with medications. In this study, 
medication adherence was not used as a primary outcome 
measure; the authors noted that the outcomes of symptom 
reduction and medication attitudes and satisfaction, rather 
than adherence, are indicators of the potential health gain 
due to the intervention.49
Other support service interventions
A variety of other support interventions were examined 
(Table 4);33,51–54 these included integrated treatment,51 
financial incentives,52 a pharmacy-based intervention,53 and 
environmental supports.33,54 Morken et al51 found that a multi-
faceted program that implemented CBT along with assertive 
outreach community treatment, family psychoeducation, and 
social skills training, did not significantly improve medica-
tion adherence compared to TAU. Priebe et al52 found that 
modest financial incentives, in the amount of $22 per clinic 
visit, to receive an LAI during a 12-month trial increased 
adherence from 75% at baseline to 85%, compared to 71% 
among controls. Greater than 95% adherence was seen in 
28% of the intervention group, compared to 5% in the con-
trol group. Valenstein et al found that, compared to controls, 
patients using a pharmacy-based intervention that included 
unit-dose prescriptions of medications for psychiatric and 
medical conditions, medication education in packaging, 
and refill reminders mailed 2 weeks in advance for 6 and 
12 months had significantly increased medication possession 
ratios (MPR, a measure that includes self-reports of adher-
ence combined with pill counts and serum labs indicating 
presence of medication).53
Environmental supports involved the use of home visits 
and adaptation of participants’ home environment to incor-
porate cues as reminders to adhere to treatment. Velligan 
et al54 found that home visits with full cognitive adaptation 
training, a tailored environmental support system aimed at 
improving independent living skills, and cognitive adaptation 
training with medication education, a tailored environmental 
support system for medication and appointment adherence, 
significantly improved medication adherence in both groups 
compared to the TAU group, and this difference remained 
significant after home visits stopped.
Discussion
Findings suggest that the utility of available support ser-
vices to enhance medication adherence depend on a variety 
of factors, such as the PWS’s attitudes toward treatment, 
perceptions of the need to take medications, and specific 
environmental and cognitive characteristics. Technological 
supports, such as mobile phone text message reminders, can 
be beneficial to PWS who are committed to medication adher-
ence and are occasionally nonadherent due to forgetfulness. 
Similarly, interventions that focus on environmental cues to 
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remind PWS to take their medications can be very helpful 
in patients with memory problems.54 In contrast, findings 
from this review suggest that therapeutic support services 
are more appropriate to PWS who are ambivalent toward 
taking medications and or deny the need to take medica-
tions. The most effective support service interventions are 
tailored to the specific needs of PWS, use a problem-solving 
approach to identify barriers to taking medications, and 
address ambivalence that PWS have toward committing to 
a life-long medication regimen.
Results of this literature review should be regarded with 
caution due to some limitations in the study designs. Adherence 
to psychiatric medications may depend on the participants’ 
age, financial constraints/affordability of medications,9 
adverse effects, severity of psychiatric symptoms, duration 
of illness, side effects, and therapeutic response. Younger 
age is a noteworthy predictor of nonadherence.4 However, 
in the studies reviewed here, only two focused on younger 
participants. One included family members as caregivers,39 in 
which the mean age of participants was 24.6±8.3 years, and 
one included participants with recent onset of symptoms;31 
the mean age of participants in this study was 25.1±4.5 years. 
In the remaining studies, the mean ages of participants ranged 
from approximately 30–50 years, which limits generalizabil-
ity to other age groups. Problems with medication adherence 
due to financial constraints and affordability of medications 
were not addressed in these studies, which is a noteworthy 
gap that warrants further research.
 Medication side effects are known contributors to poor 
medication adherence among PWS.17 However, only three 
studies in this review included a measure of side effects as 
an outcome variable. Maneesakorn et al49 found reduced 
scores on the Liverpool University Neuroleptic Side Effect 
Rating Scale in the TAU group at a 9-week follow-up; the 
authors attribute this to the higher number of participants 
who were prescribed atypical antipsychotics in the TAU 
group. Hudson et al48 found greater adherence associated with 
negative baseline akathisia score. Finally, Sajatovic et al41 
reported that in an adherence study that included LAIs, 40% 
reported akathisia, but no significant changes were seen in 
body mass index or total cholesterol. Findings from this 
review suggest that further research is warranted to exam-
ine the degree to which adverse or side effects of the more 
frequently used atypical antipsychotics influence medication 
adherence, particularly related to the emergence of obesity 
and cardiovascular/metabolic problems.
Severity of psychotic symptoms and level of cognitive 
functioning can also influence medication adherence. In the 
studies included in this review, all but four assessed symptom 
severity at the outset of the studies. Rating measures included 
the Positive and Negative Syndrome Scale, the Clinical 
Global Impressions Scale, and the Brief Psychiatric Rating 
Scale. Across all studies that measured symptoms, baseline 
symptom severity scores ranged from very mildly to mod-
erately ill. It is likely that PWS who experience very severe 
symptoms are excluded from medication adherence research 
because very severe symptoms prevent them from providing 
informed consent for participation. Consequently, research 
on medication adherence has limited generalizability toward 
PWS with severe psychotic symptoms, and unfortunately 
PWS who refuse or are unable to participate are most in need 
of support services to improve adherence. In addition, partici-
pants’ treatment response was minimal in many of the studies, 
as evidenced by nonsignificant changes in symptom severity 
scores at the conclusion of the studies.33,35,36,42,43,45,53
Several authors also reported that PWS who refused to 
participate in the studies had considerable deficits in cogni-
tive functioning. Limitations on eligibility based on cognitive 
functioning tended to limit the sample sizes, which ranged 
from 25–409; the majority of studies had less than 100 par-
ticipants. Several authors pointed out that eligibility based 
on cognitive functioning and symptoms resulted in selection 
bias, which increased the likelihood that participants had 
higher levels of functioning.49
Very little longitudinal research has been conducted on 
medication adherence over the lifetime trajectory of illness 
among PWS; the maximum duration of time included in an 
adherence study was 4 years.53 Patterns of adherence may be 
unstable over time; Valenstein et al10 investigated patterns of 
medication adherence, measured by MPR over a 4 year period 
among 34,128 veterans with schizophrenia, and the findings 
suggested that over 60% of veterans had adherence problems 
at some point during the 4 year period. Findings also indi-
cated that over a 4 year period, about 18% had consistently 
poor adherence, defined as MPRs 0.8 in all 4 years; 43% 
had inconsistent adherence, defined as MPRs 0.8 in some 
years in the observation period, and 39% had consistently 
good adherence, defined as MPRs 0.8 in all 4 years.
Very few reviewed studies focused on the effectiveness 
of support services in improving adherence to medications 
in the treatment of medical illnesses. Furthermore, it is 
important to note that in the study conducted by Beebe et al29 
the telephone intervention problem-solving intervention 
improved adherence to psychiatric medications but not to 
medications for medical illnesses. Problems with adherence 
to medications for medical illnesses are by no means unique 
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to PWS. Rates of medication nonadherence are about 50% in 
the general population,55 which is essentially identical to rates 
of nonadherence to psychiatric medications among PWS.1 
Low adherence to medications in the general population 
has been attributed to poor health literacy, intolerable side 
effects, and unaffordable copayments.55 In addition, people 
in the United States who are diagnosed with multiple chronic 
medical illnesses often receive fragmented care from several 
different providers, which results in complex medical regi-
mens consisting of multiple medications.55
PWS who have complex comorbid medical illnesses 
likely experience barriers similar to those found in the gen-
eral population, particularly related to fragmented care.26 
A supportive therapeutic alliance has been shown to promote 
medication adherence in PWS, yet Piette et al26 have observed 
that fragmented and poorly coordinated medical care from 
multiple providers in different treatment settings is a consid-
erable barrier to the development of a trusting relationship 
between patients and provider. In addition, PWS have an 
even greater risk for nonadherence compared to the general 
population due to problems with motivation and cognitive 
impairments that interfere with memory, attention, problem-
solving, and health-related decision making.56
Adherence to medications that treat psychiatric and 
medical illnesses is essential for PWS to achieve recovery 
goals and optimize overall wellness, yet ongoing research 
strongly suggests that physical health status and overall 
wellness in this population are far from ideal. PWS suffer 
from higher-than-average rates of comorbid chronic medical 
illnesses and experience worse outcomes due to these ill-
nesses compared to the general population, including higher 
rates of emergency hospital admissions, longer length of 
hospitalization for medical problems, and shorter length of 
survival.57–59 Much attention has been focused on the recent 
report that the life expectancy of PWS being served in the 
US state mental health system is 25 years shorter than that 
of the general population.60 These appalling morbidity and 
mortality statistics illustrate health disparities that are increas-
ingly untenable to patients, clinicians, policy makers, and 
family members.61–63 A comprehensive initiative to reduce 
health disparities, integrate physical and mental health care, 
and improve mental and physical health status would need 
to address multiple barriers to effective health care among 
PWS, their providers, and health care delivery systems; the 
development of more-effective support services to improve 
adherence to medications for psychiatric and medical ill-
nesses is foundational in this effort.64
Implications for practice
As this review illustrates, several strategies are available to 
prescribers to address medication adherence issues among 
PWS. The essential first step is the establishment of a trusting 
therapeutic relationship with the patient.7,16,20,21 In the event that 
inpatient hospitalization is needed, PWS should be included in 
treatment decisions as much as possible.20 Prior to implemen-
tation of support services, it is recommended that prescribers 
work with the patient to conduct a root-cause analysis of rea-
sons for nonadherence; implementation would target specific 
support strategies to address them. It is recommended that 
prescribers address adherence to psychiatric medications as a 
priority and then address adherence to medications for medi-
cal illnesses as a secondary goal, since PWS have reported 
that stable psychiatric symptoms are an essential precursor to 
effective management of medical illnesses.56,65
Prescribers can also use cognitive strategies to link medi-
cation adherence to the patient’s treatment goals, such as 
staying out of the hospital, living independently, maintaining 
normal glycemic control, or returning to work or school, as 
recommended in the Medication Treatment, Evaluation and 
Management evidence-based practice.66 Finally, prescrib-
ers can promote optimal medication adherence by regularly 
including PWS in decisions about medications and assessing 
patient knowledge and attitudes about medications through-
out the provision of support services.66
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